The Panic-Proof Portfolio (Stockchase Research)Vertex Pharmaceuticals Inc.VRTXTOP PICKJan 04, 2022

Their drugs have done great in cystic fibrosis (which has become the standard of care) and gene therapies (innovative). Their science has been at the front end of the curve.

He sold part of this. In Q1, the FDA approved a record low number of drugs, and Vertex has some important trials. Was nervous in a macro standpoint, but company fundamentals and valuation were reasonable. He hopes for a bounce.

Sold it. Long term this is great. He wrote a $19.50 covered call last Monday. Earnings slightly miss and the stock sold off. So, he hedged half the decline then got stopped out. It's pure risk management.

A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well. 

She trimmed it because it's up 20% this year because of the launch of their pain medicine. Tonight's earnings will be fine and their pipeline makes it a good stock long term.

They got disappointing news on their wonder drug. Disappointing. Doesn't see upside for the company.

He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.

Their anti-pain drug is not addictive and it works. He's a believer.

Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.

Even at this all time high don't sell. They're working on non-addictive painkillers

It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.

This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.

Likes it for its CF franchise.

Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.

PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.